Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

ADC Therapeutics

- PMLiVE

Roche’s Columvi improves survival in large B-cell lymphoma

Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

- PMLiVE

Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

This is the most common type of non-Hodgkin lymphoma worldwide

- PMLiVE

Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

The recommendation for the subcutaneous formulation follows encouraging trial data

- PMLiVE

Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma

Approximately 160,000 cases of the aggressive blood cancer are diagnosed globally every year

- PMLiVE

Roche announces positive phase 3 results for Columvi combination in DLBCL

The most common form of non-Hodgkin lymphoma affects 160,000 people worldwide every year

- PMLiVE

Sobi receives NICE recommendation for Zynlonta in two non-Hodgkin lymphomas

Over 10,000 people are diagnosed with a type of non-Hodgkin lymphoma every year in the UK

- PMLiVE

Roche’s fixed-duration lymphoma treatment approved by European Commission

Approximately 36,000 people are diagnosed with DLBCL each year in Europe

- PMLiVE

ADC Therapeutics pauses enrolment in phase 2 lymphoma study following patient deaths

Zynlonta was being evaluated along with rituximab in unfit or frail patients with DLBCL

- PMLiVE

Orphan status in Europe for lymphoma drug Zynlonta

The ADC Therapeutics antibody-drug conjugate is licensed to treat patients with a common form of non-Hodgkin lymphoma.

- PMLiVE

FDA sets January decision date for Xalkori in ALK-positive lymphoma

FDA submission is based on results from ADVL0912 and A8081013 studies

- PMLiVE

NICE recommends Roche’s Polivy for B-cell lymphoma

Cost-effectiveness agency approves drug following initial rejection earlier this year

- PMLiVE

EU grants conditional approval to Roche’s lymphoma drug Polivy

Drug demonstrated a 40% complete response rate in trial

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links